Discussing Low-Dose Naltrexone with Sajad Zalzala (News)

Discussing Low-Dose Naltrexone with Sajad Zalzala Lifespan.io 20 April 2022 https://www.lifespan.io/news/discussing-low-dose-naltrexone-with-sajad-zalzala/ This drug, known for curbing addictions, has shown other benefits in some patients. Dr. Zalzala responds to questions on the use of low dose naltrexone (LDN).

Research roundup: Recent grants and publications for Emory faculty and staff (News)

Research roundup: Recent grants and publications for Emory faculty and staff Emory News Center 12 April 2022https://news.emory.edu/stories/2022/04/er_research_roundup_april_14-04-2022/story.html Among others, a grant is: Low dose naltrexone to be studied for chronic neuropathic pain Emory pain specialist Anne Marie McKenzie-Brown has received a $50,000 grant from Cures Within Reach to study low dose naltrexone for the treatment […]

Dr Sajad Zalzala, LDN Radio Show February 2022 (LDN, low dose naltrexone)

  Dr Sajad Zalzala, LDN Radio Show February 2022 (LDN, low dose naltrexone) Dr. Sajad Zalzala is conducting very interesting trials on his patients utilizing Low Dose Naltrexone (LDN). He is collecting data on the various conditions LDN is helpful for, and what various dosages can be best in each case. His main area of […]

Repurposing low-dose naltrexone (LDN) for the prevention and treatment of immunothrombosis in COVID-19 (News)

Repurposing low-dose naltrexone (LDN) for the prevention and treatment of immunothrombosis in COVID-19 DocWire News Featured Reading 18 February 2022 https://www.docwirenews.com/abstracts/repurposing-low-dose-naltrexone-ldn-for-the-prevention-and-treatment-of-immunothrombosis-in-covid-19/ Coronavirus disease 2019 (COVID-19) is characterized by striking dysregulation of the immune system, with evidence of hyperinflammation, an impaired induction of interferons, and delayed adaptive immune responses. In addition to dysfunctional immune responses, thrombosis […]